Ozempic Discontinuation Costs: What Patients Are Paying
- Weight-loss drugs have transformed millions of lives in just a few years.
- These weekly injections act as powerful appetite suppressants, allowing patients to lose between 15 and 20% of their body weight.
- These drugs have conquered markets, transforming the treatment of diabetes and obesity in many countries.
Weight-loss drugs have transformed millions of lives in just a few years. Ozempic, Wegovy, Mounjaro: these names have become synonymous with hope for those struggling with their weight. But a new British study has documented what many already suspected: stopping these treatments is like releasing a compressed spring. And the rebound is brutal.
Initial Undeniable Effectiveness
GLP-1 agonists represent a genuine medical revolution. These weekly injections act as powerful appetite suppressants, allowing patients to lose between 15 and 20% of their body weight. in the clinical trials analyzed, participants lost an average of nearly 15 kilograms. the benefits aren’t limited to the scale: blood pressure, cholesterol levels, everything improves significantly.
Commercial success followed. These drugs have conquered markets, transforming the treatment of diabetes and obesity in many countries. But behind this enthusiasm lies a reality that researchers at the University of Oxford have now quantified precisely.
massive Discontinuation
Around half of those undergoing treatment discontinue it during the frist year. The reasons vary: unpleasant side effects such as persistent nausea, or more prosaically, the prohibitive cost. The cost of these treatments represents a major obstacle: around 200 to 300 euros per month in France where they are not yet reimbursed, and more than 1000 dollars in the United States.